Clinical Trial Detail

NCT ID NCT02310464
Title Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors OBI Pharma, Inc
Indications

lung non-small cell carcinoma

colorectal cancer

stomach cancer

lung cancer

breast cancer

Therapies

OBI-821 + OBI-833

Age Groups: adult senior

No variant requirements are available.